***Background.*** The optimal therapy for *Candida* infective endocarditis (IE) is unknown, and treatment guidelines are based largely on single site case series and case reports. The current guidelines have added echinocandins as a treatment option. We sought to compare amphotericin B based therapy to echinocandin based therapy, using two large, prospective, international, multi-center cohorts of patients with definite IE.

***Methods.*** We identified cases of definite *Candida* IE presenting between June 1, 2000 and September 30, 2011 from the International Collaboration on Endocarditis -- Prospective Cohort Study (ICE-PCS) and the International Collaboration on Endocarditis Plus (ICE-Plus). A supplemental case report form was sent to enrolling sites to gather detailed information on antifungal therapy. We compared clinical characteristics and outcomes based on antifungal regimen received.

                                       Amphotericin B (N=11)   Echinocandin (N=14)   p-value
  ------------------------------------ ----------------------- --------------------- ---------
  Combination therapy                  6 (54%)                 6 (43%)               0.56
  Surgery                              6 (54%)                 5 (36%)               0.35
  Duration antifungal, days (median)   78                      50                    0.89
  Suppressive therapy                  5 (45%)                 6 (43%)               0.90
  Mortality                                                                          
  42 d                                 4 (36%)                 5 (36%)               1
  1 y                                  7 (64%)                 9 (69%)               1

***Results.*** 72 cases of definite *Candida* IE were identified of which 33 had additional data on antifungal therapy available. The most common infecting species were *C. albicans* (n = 13) and *C. parapsilosis* (n = 12). Most patients received either an amphotericin B based regimen (33%) or an echinocandin based regimen (42%). Nearly half received combination antifungal therapy (45%) and surgical therapy was used in 13 patients (39%). There was no difference in either 42 day or 1 year mortality between those receiving an amphotericin B based regimen vs those receiving an echinocandin based regimen (36% vs 36% and 64% vs 69%, respectively, p = 1).

***Conclusion.*** This is one of the largest prospective series of *Candida* endocarditis patients to date. In this cohort, there was no difference in mortality with echinocandin based therapy as compared to amphotericin B based therapy. This study is limited by small sample size and observational data, however it lends support to the current recommendation of echinocandin based therapy as a viable treatment option for *Candida* endocarditis.
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